Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
PCRX•Viatris agreed to buy Pacira BioSciences for $1.65 billion in cash, or $36.50 per share, a 44.8% premium to Pacira’s last close. Pacira shares rose 44% to $36.30, while Viatris shares slipped 2.6%.
1. Cash acquisition
Viatris will buy Pacira BioSciences for $1.65 billion in cash, paying $36.50 per share. The offer represents a premium of about 44.8% to Pacira’s last closing price of $25.20. The companies expect the deal to close by the end of 2026.
2. Shares and products
Pacira shares rose 44% to a more than three-year high of $36.30 and were on track for their biggest one-day gain on record if the gains held. Viatris shares slipped 2.6%. The deal adds Pacira’s non-opioid pain drugs Exparel and Zilretta to Viatris’ portfolio.
3. Analyst view
J.P. Morgan said it did not see the acquisition significantly changing Viatris’ broader financial profile in the near or longer term, and anticipated gradual erosion for Exparel from 2030 onward due to generic entry.
